P. Kirschmeier

发表

Analyses of p53 Target Genes in the Human Genome by Bioinformatic and Microarray Approaches* 210

Yaolin Wang, Luquan Wang, Luquan Wang, 2001, The Journal of Biological Chemistry.

Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression

Luquan Wang, Beth Hutchins, Ferdous Gheyas, 2003, Oncogene.

AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines

P. Kirschmeier, S. Koseoglu, Zhuomei Lu, 2007, Cancer biology & therapy.

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

E. Lees, T. Fischmann, P. Kirschmeier, 2010, Molecular Cancer Therapeutics.

linical Development aciclib ( SCH 727965 ) , a Novel and Potent Ther lin-Dependent Kinase Inhibitor

Parry, E. Lees, P. Kirschmeier, 2010 .

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

C. Paweletz, P. Jänne, D. Jackman, 2014, Clinical Cancer Research.

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Shuxia Zhao, Leigh Zawel, Stephen Fawell, 2013, Cancer discovery.

Transcriptional Regulation during p21 WAF1/CIP1 -induced Apoptosis in Human Ovarian Cancer Cells*

Luquan Wang, T. Mcclanahan, Tong-Yuan Yang, 2002, The Journal of Biological Chemistry.

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.

Henry W. Long, R. Beroukhim, C. Paweletz, 2020, Cancer cell.

Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.

M. Snow, P. Weber, P. Kirschmeier, 2002, Journal of medicinal chemistry.

Construction and characterization of a retroviral vector demonstrating efficient expression of cloned cDNA sequences.

I. Weinstein, A. Perkins, P. Kirschmeier, 1988, DNA.

Identification and characterization of zinc binding sites in protein kinase C.

W. R. Bishop, S. Hubbard, W. Hendrickson, 1991, Science.

Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.

J. English, P. Kirschmeier, W. Windsor, 2014, Journal of medicinal chemistry.

Farnesyl Transferase Inhibitors: Mechanism of Action, Translational Studies and Clinical Evaluation

W. R. Bishop, C. Baum, P. Kirschmeier, 2003, Cancer biology & therapy.

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.

W. R. Bishop, E. Maxwell, Marnie McGuirk, 2001, Experimental cell research.

Tricyclic Farnesyl Protein Transferase Inhibitors: Antitumor Activity and Effects on Protein Prenylation

W. R. Bishop, P. Kirschmeier, L. Armstrong, 2000 .

Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice

Walter A. Korfmacher, W. R. Bishop, Jianping Chen, 1999, Cancer Chemotherapy and Pharmacology.

Novel Tricyclic Inhibitors of Farnesyl Protein Transferase

W. R. Bishop, P. Kirschmeier, J. Schwartz, 1995, The Journal of Biological Chemistry.

Farnesyl Transferase Inhibitors: From Targeted Cancer Therapeutic to a Potential Treatment for Progeria

W. R. Bishop, P. Kirschmeier, R. Doll, 2011 .

Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.

W. R. Bishop, J. English, P. Kirschmeier, 2002, Experimental cell research.

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.

W. R. Bishop, G. Daley, P. Kirschmeier, 2001, Blood.

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma

P. Sorger, K. Ligon, G. Freeman, 2020, Clinical Cancer Research.

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.

C. Paweletz, D. Barbie, Y. Mitsuishi, 2018, Cancer discovery.

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Andrew H. Beck, A. Khosla, A. Beck, 2019, Cancer Immunology Research.

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

C. Paweletz, A. Redig, P. Jänne, 2018, Clinical Cancer Research.

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

E. Lees, T. Fischmann, P. Kirschmeier, 2010, ACS medicinal chemistry letters.

Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336)

P. Kirschmeier, Ming Liu, A. Basso, 2007, Anti-cancer drugs.

Preclinical and clinical evaluation of farnesyltransferase inhibitors

C. Baum, P. Kirschmeier, 2003, Current oncology reports.

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Edward S. Kim, W. R. Bishop, P. Thall, 2004, Clinical Cancer Research.

Inhibitors of farnesyl protein transferase. Synthesis and biological activity of amide and cyanoguanidine derivatives containing a 5,11-dihydro[1]benzthiepin, benzoxepin, and benzazepin [4,3-b]pyridine ring system.

W. R. Bishop, P. Kirschmeier, J. Weinstein, 1998, Bioorganic & medicinal chemistry letters.

In vivo prenylation analysis of Ras and Rho proteins.

W. R. Bishop, D. Whyte, P. Kirschmeier, 2001, Methods in enzymology.

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

J. Nemunaitis, P. Kirschmeier, Ying‐Ming Jou, 2013, Journal of Translational Medicine.

Design of a Retrovirus-Derived Vector for Expression and Transduction of Exogenous Genes in Mammalian Cells

I. Weinstein, A. Perkins, P. Kirschmeier, 1983, Molecular and cellular biology.

Cellular Moloney murine sarcoma (c-mos) sequences are hypermethylated and transcriptionally silent in normal and transformed rodent cells

I. Weinstein, P. Kirschmeier, J. Escobedo, 1982, Molecular and cellular biology.

Specific DNA Sequences in C3H 1OT1/2 Cells

P. Kirschmeier, S. Gattoni-Celli, W. Hsiao, 2022 .

Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models.

W. R. Bishop, P. Kirschmeier, L. Nielsen, 2001, Methods in enzymology.

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

D. Hicklin, P. Kirschmeier, Ming Liu, 2010 .

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

D. Hicklin, P. Kirschmeier, Ming Liu, 2010, Molecular Cancer Therapeutics.

Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation.

W. R. Bishop, M. Snow, P. Kirschmeier, 1997, Bioorganic & medicinal chemistry.

chronic myeloid leukemia BCR/ABL-induced murine leukemia and primary cells from patients with Activity of the farnesyl protein transferase inhibitor SCH66336 against

W. R. Bishop, G. Daley, P. Kirschmeier, 2013 .

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

G. Martinelli, T. Holyoake, J. Lipton, 2008, Leukemia.

ORIGINAL ARTICLE On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia

T. Holyoake, D. DeAngelo, P. Kirschmeier, 2008 .

Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.

I. Pollack, P. Kirschmeier, R. Packer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd

C. Paweletz, P. Jänne, J. Köhler, 2021, Cancer Research.

Molecular cloning of gene sequences regulated by tumor promoters and mitogens through protein kinase C

I. Weinstein, P. Kirschmeier, M. Johnson, 1987, Molecular and cellular biology.

Transduction of the human insulin gene via retroviral vectors fails to yield spliced transcripts.

I. Weinstein, P. Kirschmeier, A. Perkins, 1989, DNA.

Detection and structural characterization of ras oncoprotein-inhibitors complexes by electrospray mass spectrometry.

S. Liberles, J. Brown, M. Snow, 1997, Bioorganic & medicinal chemistry.

Synthesis and evaluation of pyrazolo[3,4-b]quinoline ribofuranosides and their derivatives as inhibitors of oncogenic Ras

P. Kirschmeier, A. McPhail, J. Kelly, 1996 .

New Insights into Tumor Promotion from Molecular Studies of Protein Kinase C

Mark D. Johnson, I. Weinstein, P. Kirschmeier, 1988 .

Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities.

W. R. Bishop, P. Kirschmeier, R. Doll, 1999, Journal of medicinal chemistry.

Molecular mechanisms of tumor promotion and multistage carcinogenesis.

P. Kirschmeier, A. Jeffrey, J. Backer, 1983 .

SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors

F. Monsma, D. Hicklin, P. Kirschmeier, 2011, Cancer Chemotherapy and Pharmacology.

COMPLEXITY IN THE REGULATION OF SOS FUNCTIONS IN BACTERIA

P. Kirschmeier, E. Witkin, 1978 .

Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex.

L. Perkins, S. Liberles, J. Brown, 1997, Bioorganic & medicinal chemistry.

Prognostic and Predictive Molecular Markers in Cutaneous Malignant Melanoma: The First Step Toward Personalized Medicine

P. Kirschmeier, Suxing Liu, C. Seidel-Dugan, 2008 .

Farnesyltransferase inhibitors as anticancer agents: critical crossroads.

W. R. Bishop, P. Kirschmeier, R. Doll, 2004, Current opinion in drug discovery & development.

Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005.

W. R. Bishop, P. Kirschmeier, A. Basso, 2006, Journal of Lipid Research.

Farnesyl transferase inhibitors

P. Kirschmeier, A. Basso, R. Bishop, 2005 .

- 1-Lipid Posttranslational Modifications : Farnesyl Transferase Inhibitors

P. Kirschmeier, A. Basso, 2005 .

Overproduction of protein kinase C causesdisordered growth control in rat fibroblasts

Mark D. Johnson, I. Weinstein, P. Kirschmeier, 1988, Cell.

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.

C. Paweletz, P. Hammerman, P. Lizotte, 2020, The Journal of clinical investigation.

New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.

P. Kirschmeier, Ming Liu, A. Nomeir, 2014, Bioorganic & Medicinal Chemistry Letters.

Discovery of C-imidazole azaheptapyridine FPT inhibitors.

W. R. Bishop, P. Kirschmeier, R. Doll, 2010, Bioorganic & medicinal chemistry letters.

K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors*

W. R. Bishop, D. Whyte, P. Kirschmeier, 1997, The Journal of Biological Chemistry.

The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling

W. R. Bishop, A. Mirza, P. Kirschmeier, 2005, Journal of Biological Chemistry.

Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.

C. Baum, P. Kirschmeier, A. Taveras, 2003, Current topics in medicinal chemistry.

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

W. R. Bishop, J. Sloan, J. Sloan, 2000, Cancer research.

Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification*

C. Der, N. Mitin, P. Roberts, 2008, Journal of Biological Chemistry.

Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.

P. Tamayo, R. Neve, Kwok-Kin Wong, 2018, Cancer cell.

Semi-synthetic aristolactams--inhibitors of CDK2 enzyme.

T. Fischmann, P. Kirschmeier, V. Madison, 2010, Bioorganic & medicinal chemistry letters.

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

Jennifer L Moseley, L. Chirieac, G. Shapiro, 2017, British Journal of Cancer.

Development of a Fluorescence Polarization Bead-Based Coupled Assay to Target Different Activity/Conformation States of a Protein Kinase

P. Kirschmeier, C. Kumar, S. Koseoglu, 2004, Journal of biomolecular screening.

Biological effects and mechanism of action of farnesyl transferase inhibitors.

W. R. Bishop, P. Kirschmeier, L. Armstrong, 2000, Chemical research in toxicology.

Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules*

W. R. Bishop, P. Kirschmeier, L. Armstrong, 2000, The Journal of Biological Chemistry.

A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results.

L. Chirieac, G. Shapiro, S. Rodig, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.

J. Nemunaitis, P. Kirschmeier, D. Khaira, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Zhi Wei, Hongye Liu, Wei Huang, 2018, Cancer discovery.

A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing

P. Jänne, N. Gray, P. Lizotte, 2018, Cancer Immunology Research.

Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

C. Paweletz, P. Jänne, J. Köhler, 2021, Molecular Cancer Therapeutics.

Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity

P. Hammerman, Kwok-Kin Wong, G. Dranoff, 2019, Journal of Immunotherapy for Cancer.

Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3

H. Hirsch, Kwok-Kin Wong, P. Janne, 2014, Molecular Cancer Research.

(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.

W. R. Bishop, P. Kirschmeier, L. Wang, 1998, Journal of medicinal chemistry.

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway

W. R. Bishop, Luquan Wang, Qun Wu, 2002, Oncogene.

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models

W. R. Bishop, P. Kirschmeier, B. Long, 2009, International journal of cancer.

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.

W. R. Bishop, P. Kirschmeier, Ming Liu, 2008, Gynecologic oncology.

Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.

W. R. Bishop, P. Kirschmeier, F. G. Njoroge, 2004, Bioorganic & medicinal chemistry letters.

Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability.

P. Kirschmeier, A. Nomeir, F. G. Njoroge, 2004, Bioorganic & medicinal chemistry letters.

Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferase.

W. R. Bishop, P. Weber, P. Kirschmeier, 2002, Bioorganic & medicinal chemistry letters.

Multistage carcinogenesis involves multiple genes and multiple mechanisms

P. Kirschmeier, M. Lambert, I. Weinstein, 1984, Journal of cellular physiology. Supplement.

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

Charles Y. Lin, Mousheng Xu, J. Qi, 2018, eLife.

Targeting MYC dependency in ovarian cancer through inhibition of 1 CDK 7 and CDK 12 / 13 2

Charles Y. Lin, Mousheng Xu, J. Qi, 2022 .

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

G. Mills, C. Paweletz, V. Velculescu, 2016, Clinical Cancer Research.

Synthesis of (5,6‐Dihydro‐11H‐benzo[5,6]cyclohepta [1,2‐b]pyridin‐11‐ylidene)‐1‐piperidine‐N‐cyanoguanidine Derivatives (I) as Inhibitors of Ras Farnesyl Protein Transferase.

W. R. Bishop, P. Weber, P. Kirschmeier, 2002 .

Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine.

Walter A. Korfmacher, W. R. Bishop, J. Chen, 1998, Journal of medicinal chemistry.

Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase.

W. R. Bishop, N. Carruthers, P. Kirschmeier, 1997, Bioorganic & medicinal chemistry.

Bridgehead Modification of Trihalocycloheptabenzopyridine Lead to a Potent Farnesyl Protein Transferase Inhibitor with Improved Oral Metabolic Stability.

P. Kirschmeier, A. Nomeir, F. G. Njoroge, 2005 .

Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors

Kathleen M. Smith, T. Mcclanahan, P. Kirschmeier, 2006, Cancer biology & therapy.

Chemical shift assignments and secondary structure of the Grb2 SH2 domain by heteronuclear NMR spectroscopy

L. Perkins, M. Senior, P. Kirschmeier, 1996, Journal of biomolecular NMR.

Indolocarbazoles. 1. Total synthesis and protein kinase inhibiting characteristics of compounds related to K-252c.

P. Kirschmeier, B. Shankar, J. Petrin, 1993 .

Role of protein kinase C in regulation of gene expression and relevance to tumor promotion.

I. Weinstein, P. Kirschmeier, M. Johnson, 1987, Environmental health perspectives.

Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells

D. Neuberg, G. Tonon, J. Asara, 2015, Leukemia.

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

Geoffrey R. Oxnard, C. Paweletz, P. Jänne, 2015, Clinical Cancer Research.

Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I*

W. R. Bishop, P. Kirschmeier, W. Windsor, 1997, The Journal of Biological Chemistry.

Effects of 5-azacytidine on methylation and expression of specific DNA sequences in C3H 10T1/2 cells

I. Weinstein, P. Kirschmeier, W. Hsiao, 1984, Molecular and cellular biology.

Integrative Genomics Revealed RAI3 Is a Cell Growth-promoting Gene and a Novel P53 Transcriptional Target*

W. R. Bishop, T. Mcclanahan, Qun Wu, 2005, Journal of Biological Chemistry.

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

G. Shapiro, A. D’Andrea, U. Matulonis, 2019, Clinical Cancer Research.

Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations

P. Jänne, N. Gray, M. Capelletti, 2020, Molecular oncology.

Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C

Michael S. Goldberg, J. Jenkins, W. Forrester, 2017, The Journal of clinical investigation.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

W. R. Bishop, R. Sullivan, K. Flaherty, 2018, JCI insight.

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

G. Mills, E. Winer, W. Barry, 2019, The Lancet. Oncology.

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.

K. Cox, P. Kirschmeier, R. Doll, 2018, ACS medicinal chemistry letters.

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.

P. Kirschmeier, R. Doll, W. Windsor, 2018, Bioorganic & medicinal chemistry letters.

Signal Transduction Evaluating TBK 1 as a Therapeutic Target in Cancers with Activated IRF 3

Kwok-Kin Wong, L. Zawel, P. Kirschmeier, 2015 .

An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach.

P. Kirschmeier, H. Davis, K. Treinen, 2009, Toxicology.

Isolation of cDNA clones encoding protein kinase C: evidence for a protein kinase C-related gene family.

I. Weinstein, P. Kirschmeier, M. Johnson, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Lipid posttranslational modifications. Farnesyl transferase inhibitors.

W. R. Bishop, P. Kirschmeier, A. Basso, 2006, Journal of lipid research.

Expression of long terminal repeat (LTR) sequences in carcinogen-induced murine skin carcinomas.

I. Weinstein, P. Kirschmeier, S. Garte, 1985, Biochemical and biophysical research communications.

Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.

Patrick J. Curran, E. Lees, T. Fischmann, 2013, Bioorganic & medicinal chemistry letters.

Carcinogen- and radiation-transformed C3H 10T1/2 cells contain RNAs homologous to the long terminal repeat sequence of a murine leukemia virus.

I. Weinstein, P. Kirschmeier, D. Dina, 1982, Proceedings of the National Academy of Sciences of the United States of America.

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer

C. Paweletz, P. Jänne, W. Barry, 2018, npj Breast Cancer.

Interaction of a novel GDP exchange inhibitor with the Ras protein.

J. Brown, M. Snow, C. Kissinger, 1998, Biochemistry.

Abstract 2796: Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity

R. Drapkin, G. Shapiro, A. D’Andrea, 2017 .

Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity.

W. R. Bishop, P. Kirschmeier, R. Doll, 1999, Bioorganic & Medicinal Chemistry.

Molecular Cloning ofGeneSequences Regulated byTumor Promoters andMitogens through Protein Kinase C

Mark D. Johnson, P. Kirschmeier, G. Housey, 1987 .

Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo

David A. Orlando, N. Rajagopal, U. Matulonis, 2018, Molecular and Cellular Biology / Genetics.

In vitro and in vivo characterization of SCH727965 a novel potent cyclin dependent kinase inhibitor

E. Lees, P. Kirschmeier, Yaolin Wang, 2007 .

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer

E. Winer, C. Paweletz, P. Jänne, 2018, npj Breast Cancer.

IMMU-15. PD-1 BLOCKADE ACTIVATES CD4 T CELLS AND THE INNATE IMMUNE RESPONSE FOR GLIOBLASTOMA ERADICATION

Kristen L Jones, D. Reardon, P. Kirschmeier, 2017 .

SCH 727965, a novel cyclin-dependent kinase inhibitor, has potent anti-tumor acitivity in a wide-spectrum of human tumor xenograft models

Lingling Wu, D. Hicklin, E. Lees, 2008 .

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

D. Hicklin, P. Kirschmeier, Ming Liu, 2010, Molecular Cancer Therapeutics.

Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C

Michael S. Goldberg, J. Jenkins, W. Forrester, 2017, The Journal of clinical investigation.

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics

G. Mills, C. Paweletz, V. Velculescu, 2016, Clinical Cancer Research.

Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.

P. Tamayo, R. Neve, Xiaoen Wang, 2018, Cancer cell.

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models

P. Kirschmeier, B. Long, Y. Hsieh, 2009, International journal of cancer.

Benzo[a]pyrene induction of extrachromosomal viral DNA synthesis in rat cells transformed by polyoma virus.

I. Weinstein, P. Kirschmeier, M. Lambert, 1983, Carcinogenesis.

Novel Tricyclic Inhibitors of Farnesyl Protein Transferase BIOCHEMICAL CHARACTERIZATION AND INHIBITION OF Ras MODIFICATION IN TRANSFECTED Cos CELLS*

P. Kirschmeier, J. Catino, R. Doll, 1995 .

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

D. Hicklin, P. Kirschmeier, Ming Liu, 2010 .

SCH 2047069, a Novel Oral Kinesin Spindle Protein Inhibitor, Shows Single-Agent Antitumor Activity and Enhances the Efficacy of Chemotherapeutics

D. Hicklin, P. Kirschmeier, Ming Liu, 2010, Molecular Cancer Therapeutics.